Moreover, although parp4 and CHEK2 mutations are important markers (1, 29), the association between certain classic markers, such as thyroid autoantibodies, thyroid hormone receptors α and β, estrogen receptor α, and breast and thyroid cancers requires further exploration (30–32). This evidence concerns the gene CHEK2 and thyroid gland carcinoma.